Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists
- 20 November 2020
- journal article
- review article
- Published by Wiley in IUBMB Life
- Vol. 73 (1) , 10-25
Abstract
At the forefront of the battle against pathogens or any endogenously released molecules, toll‐like receptors (TLRs) play an important role as the most noble pattern recognition receptors. The ability of these receptors in distinguishing “self” and “non‐self” antigens is a cornerstone in the innate immunity system; however, misregulation links inflammatory responses to the development of human cancers. It has been known for some time that aberrant expression and regulation of TLRs not only endows cancer cells an opportunity to escape from the immune system but also supports them through enhancing proliferation and angiogenesis. Over the past decades, cancer research studies have witnessed a number of preclinical and clinical breakthroughs in the field of TLR modulators and some of the agents have exceptionally performed well in advanced clinical trials. In the present review, we have provided a comprehensive review of different TLR agonists and antagonists and discuss their limitations, toxicities, and challenges to outline their future incorporation in cancer treatment strategies.Keywords
This publication has 122 references indexed in Scilit:
- Nano‐particle vaccination combined with TLR‐7 and ‐9 ligands triggers memory and effector CD8+T‐cell responses in melanoma patientsEuropean Journal of Immunology, 2012
- Targeting pattern recognition receptors in cancer immunotherapyTargeted Oncology, 2012
- Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaBritish Journal of Haematology, 2009
- Increasing the Antigenicity of Synthetic Tumor‐Associated Carbohydrate Antigens by Targeting Toll‐Like ReceptorsChemBioChem, 2009
- Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasisNature, 2009
- Toll-like receptors and cancerNature Reviews Cancer, 2008
- Role of neutrophils in BCG immunotherapy for bladder cancerUrologic Oncology: Seminars and Original Investigations, 2008
- Functional diversification of the toll-like receptor gene familyImmunogenetics, 2008
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-primingProceedings of the National Academy of Sciences, 2007
- Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?British Journal of Cancer, 2006